Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Dukoral vaccination with intranasal cholera rechallenge model in healthy volunteers
NL-OMON53390Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Apr 2023
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial of cholera toxin B subunit, recombinant cholera toxin subunit B, mycophenolate mofetil and Placebo-COD Research Private Ltd (2 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Serum cholera antigen specific IgA and Serum cholera antigen specific IgG. Started Apr 2023; status: active, not recruiting.
02
Drugs
cholera toxin B subunitrecombinant cholera toxin subunit Bmycophenolate mofetilPlacebo-COD Research Private Ltd
Beyond the preview
Go deeper on NL-OMON53390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53390.